التفاصيل البيبلوغرافية
| العنوان: |
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. |
| المؤلفون: |
Macdonell, Richard, Nagels, Guy, Laplaud, David-Axel, Pozzilli, Carlo, de Jong, Brigit, Martins da Silva, Ana, Nicholas, Richard, Lechner-Scott, Jeannette, Gaebler, Julia A., Agarwal, Sonalee, Wang, Ping, Yeh, Michael, Hovenden, Maria, Soelberg Sørensen, Per |
| المصدر: |
Multiple Sclerosis Journal; Jun2016, Vol. 22 Issue 7, p944-954, 11p, 1 Diagram, 4 Charts, 1 Graph |
| مصطلحات موضوعية: |
HEALTH impact assessment, MULTIPLE sclerosis, PHARMACEUTICAL research, WALKING, MENTAL health |
| مستخلص: |
Background: Multiple sclerosis (MS) is a debilitating disease that negatively impacts patients’ lives. Objective: ENABLE assessed the effect of long-term prolonged-release (PR) fampridine (dalfampridine extended release in the United States) treatment on patient-perceived health impact in patients with MS with walking impairment. Methods: ENABLE was a 48-week, open-label, Phase 4 study of PR-fampridine 10 mg twice daily. Patients who showed any improvement in Timed 25-Foot Walk walking speed at weeks 2 and 4 and any improvement in 12-item MS Walking Scale score at week 4 remained on treatment. The primary endpoint was change from baseline in 36-Item Short-Form Health Survey (SF-36) physical component summary (PCS) score. Results: At week 4, 707/901 (78.5%) patients met the criteria to remain on treatment. Patients on treatment demonstrated significant and clinically meaningful improvements in SF-36 PCS scores from baseline (mean change (95% confidence interval)) to week 12 (4.30 (3.83, 4.78); p < 0.0001), week 24 (3.75 (3.23, 4.27); p < 0.0001), week 36 (3.46 (2.95, 3.97); p < 0.0001), and week 48 (3.24 (2.72, 3.77); p < 0.0001). Significant improvements from baseline were also demonstrated in secondary health measures in patients on treatment. Conclusion: PR-fampridine improved patient-perceived physical and psychological health impact of MS measured in a real-life setting. [ABSTRACT FROM AUTHOR] |
|
Copyright of Multiple Sclerosis Journal is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
